Department of Physiology, and Hypertension and Renal Center of Excellence, Tulane University Health Sciences Center, New Orleans, LA 70112-2699, USA.
Am J Nephrol. 2010;31(4):318-25. doi: 10.1159/000286037. Epub 2010 Feb 15.
We recently reported that immunoreactivity of intrarenal angiotensinogen (AGT) is significantly increased in IgA nephropathy patients. Meanwhile, we have developed direct enzyme-linked immunosorbent assays to measure plasma and urinary AGT (UAGT) in humans. This study was performed to test the hypothesis that UAGT levels are increased in chronic glomerulonephritis patients.
We analyzed 100 urine samples from 70 chronic glomerulonephritis patients (26 from IgA nephropathy, 24 from purpura nephritis, 8 from lupus nephritis, 7 from focal segmental glomerulosclerosis, and 5 from non-IgA mesangial proliferative glomerulonephritis) and 30 normal control subjects.
UAGT-creatinine ratio (UAGT/UCre) was correlated positively with diastolic blood pressure (p = 0.0326), urinary albumin-creatinine ratio (p < 0.0001), urinary protein-creatinine ratio (p < 0.0001) and urinary occult blood (p = 0.0094). UAGT/UCre was significantly increased in chronic glomerulonephritis patients not treated with renin-angiotensin system (RAS) blockers compared with control subjects (p < 0.0001). Importantly, glomerulonephritis patients treated with RAS blockers had a marked attenuation of this augmentation (p = 0.0021).
These data indicate that UAGT are increased in chronic glomerulonephritis patients and treatment with RAS blockers suppressed UAGT. The efficacy of RAS blockade to reduce the intrarenal RAS activity can be confirmed by measurement of UAGT in chronic glomerulonephritis patients.
我们最近报道称,IgA 肾病患者肾内血管紧张素原(AGT)的免疫反应性显著增加。同时,我们已经开发了直接酶联免疫吸附测定法来测量人类的血浆和尿液 AGT(UAGT)。本研究旨在检验 UAGT 水平在慢性肾小球肾炎患者中升高的假设。
我们分析了 70 例慢性肾小球肾炎患者(26 例 IgA 肾病,24 例紫癜性肾炎,8 例狼疮性肾炎,7 例局灶节段性肾小球硬化症,5 例非 IgA 系膜增生性肾小球肾炎)和 30 例正常对照者的 100 份尿液样本。
UAGT-肌酐比值(UAGT/UCre)与舒张压呈正相关(p=0.0326),与尿白蛋白-肌酐比值(p<0.0001)、尿蛋白-肌酐比值(p<0.0001)和尿潜血(p=0.0094)呈正相关。未经肾素-血管紧张素系统(RAS)阻滞剂治疗的慢性肾小球肾炎患者的 UAGT/UCre 明显高于对照组(p<0.0001)。重要的是,RAS 阻滞剂治疗的肾小球肾炎患者的这种增加明显减弱(p=0.0021)。
这些数据表明,UAGT 在慢性肾小球肾炎患者中增加,RAS 阻滞剂治疗可抑制 UAGT。通过测量慢性肾小球肾炎患者的 UAGT,可以证实 RAS 阻断对减少肾内 RAS 活性的疗效。